ID   VOA3723
AC   CVCL_VQ41
SY   VOA-3723
DR   cancercelllines; CVCL_VQ41
DR   Wikidata; Q98134547
RX   DOI=10.14288/1.0319145;
RX   PubMed=27822414;
CC   Sequence variation: Mutation; HGNC; HGNC:6307; KDR; Simple; p.Gln472His (c.1416A>T); ClinVar=VCV000134603; Zygosity=Heterozygous (PubMed=27822414).
CC   Sequence variation: Mutation; HGNC; HGNC:7029; MET; Simple; p.Asn375Ser (c.1124A>G); ClinVar=VCV000041611; Zygosity=Heterozygous (PubMed=27822414).
CC   Sequence variation: Mutation; HGNC; HGNC:8975; PIK3CA; Simple; p.Ile391Met (c.1173A>G); ClinVar=VCV000135038; Zygosity=Heterozygous (PubMed=27822414).
ST   Source(s): PubMed=27822414
ST   Amelogenin: X
ST   CSF1PO: 9,14
ST   D13S317: 9,10
ST   D16S539: 10,13
ST   D21S11: 28,29
ST   D5S818: 10,11
ST   D7S820: 12
ST   TH01: 9,9.3
ST   TPOX: 8,11
ST   vWA: 16,17
DI   NCIt; C105556; Low grade ovarian serous adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_VQ40 ! VOA3448
SX   Female
AG   42Y
CA   Cancer cell line
DT   Created: 07-09-18; Last updated: 19-12-24; Version: 7
//
RX   DOI=10.14288/1.0319145;
RA   Dawson A.;
RT   "Targeted therapy in low-grade serous ovarian carcinoma:
RT   characterization of MEK inhibitor response in novel patient-derived
RT   cell lines.";
RL   Thesis PhD (2016); University of British Columbia; Vancouver; Canada.
//
RX   PubMed=27822414; PMCID=PMC5088288;
RA   Fernandez M.L., DiMattia G.E., Dawson A., Bamford S., Anderson S.,
RA   Hennessy B.T., Anglesio M.S., Shepherd T.G., Salamanca C.M.,
RA   Hoenisch J., Tinker A., Huntsman D.G., Carey M.S.;
RT   "Differences in MEK inhibitor efficacy in molecularly characterized
RT   low-grade serous ovarian cancer cell lines.";
RL   Am. J. Cancer Res. 6:2235-2251(2016).
//